Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Drug guidance

Review of cancer drugs for acute lymphoblastic leukaemia

Condition

Blood and Immune System

Cancer

1 April 2026

Published on 04 Jan 2022
Last Updated on 1 Apr 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Blinatumomab powder for infusion 35 mcg/vial;

  • Dasatinib 20 mg, 50 mg and 70 mg tablets;

  • Ponatinib 15 mg tablets; and

  • Inotuzumab ozogamicin 1 mg powder for concentrate for solution for infusion

for treating acute lymphoblastic leukaemia (ALL) in line with specific clinical criteria.

Subsidy status

Blinatumomab powder for infusion 35 mcg/vial is recommended for inclusion on the Medication Assistance Fund (MAF) with effect from 4 January 2022a for treating patients with B-precursor ALL in first or subsequent complete remission with minimal residual disease (MRD) for:

  • up to a maximum of one cycle for induction in a lifetime for this indication; and

  • up to three additional cycles for consolidation in a lifetime for this indication.

Dasatinib 20 mg, 50 mg and 70 mg tablets are recommended for inclusion on MAF with effect from 1 September 2022 for treating patients with:

  • newly diagnosed Philadelphia chromosome positive ALL (Ph+ ALL) in combination with chemotherapy; or

  • Ph+ ALL with resistance or intolerance to prior treatment with imatinib.

Ponatinib 15 mg tablet is recommended for inclusion on MAF with effect from 1 September 2022 for treating patients:

  • with Ph+ ALL who are resistant to dasatinib;

  • who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or

  • who have the T315I mutation.

Inotuzumab ozogamicin 1 mg powder for concentrate for solution for infusion is recommended for inclusion on MAF with effect from 1 April 2022 for treating patients with relapsed or refractory CD22 positive B-precursor ALL for:

  • up to a maximum of three cycles for induction in a lifetime; and

  • up to three additional cycles for consolidation in a lifetime for patients who achieve a complete response after induction.

Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.

arevised clinical indication with effect from 1 Apr 2026.

Review of cancer drugs for acute lymphoblastic leukaemia (Updated 1 Apr 2026) [PDF, 184 KB]

PES Treatments for acute lymphoblastic leukaemia (Published 4 Jan 2022) [PDF, 160 KB]

Back to top